What goes up must come down: biomarkers and novel biologicals in severe asthma
B. Hilvering
Department of Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Department of Respiratory Medicine, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
Search for more papers by this authorCorresponding Author
I. D. Pavord
Department of Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Correspondence:
Ian Pavord, Professor of Respiratory Medicine, NDM Research Building, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7FZ, UK.
E-mail: [email protected]
Search for more papers by this authorB. Hilvering
Department of Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Department of Respiratory Medicine, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
Search for more papers by this authorCorresponding Author
I. D. Pavord
Department of Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Correspondence:
Ian Pavord, Professor of Respiratory Medicine, NDM Research Building, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7FZ, UK.
E-mail: [email protected]
Search for more papers by this authorSummary
Asthma is a heterogeneous airway disease characterized by typical symptoms in combination with variable airway obstruction. Most patients with asthma have well controlled symptoms and a low risk of asthma attacks with inhaled corticosteroid (ICS) treatment. However, a clinically important subgroup (~ 10%) remains symptomatic and/or at risk of asthma attacks despite maximum inhaled therapy. Patients with severe asthma are responsible for a significant proportion of healthcare costs attributable to asthma and have a large unmet need for better treatments. An important advance in recent years has been the recognition that severe asthma is heterogeneous with respect to clinical problems and the pattern of lower airway inflammation. Identification of eosinophilic inflammation in the airways has become an important priority as novel biologicals that target Th2 cytokines, such as anti-IL5, anti-IL-13 and combined anti-IL-4/13 are showing considerable promise as treatments for this subgroup. It has also become clear that anti-IgE (Omalizumab), the first monoclonal antibody registered for treatment of severe asthma, is only active in patients with active eosinophilic airway inflammation. The future will be identification of potentially responsive patients on the basis of raised biomarkers and, as suggested by the title of this review, targeted treatment with specific cytokine blockade that has a direct effect on the biomarkers. In this review, we outline an approach to the clinical assessment of patients potentially suitable for biological treatment and describe in detail the likely clinical impact of established and new biological treatments.
References
- 1British guideline on the management of asthma. Thorax 2008; 63(Suppl. 4): iv1–121.
10.1136/thx.2008.097741 Google Scholar
- 2Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368: 780–93.
- 3Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143–78.
- 4Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–73.
- 5Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol 2011; 128: 1165–74.
- 6 From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. Available from: http://www.ginasthma.org/ (Last accessed 20 December 2014).
- 7Weinberger M, Abu-Hasan M. Pseudo-asthma: when cough, wheezing, and dyspnea are not asthma. Pediatrics 2007; 120: 855–64.
- 8Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22: 478–83.
- 9Hunter CJ, Brightling CE, Woltmann G, Wardlaw AJ, Pavord ID. A comparison of the validity of different diagnostic tests in adults with asthma. Chest 2002; 121: 1051–7.
- 10Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218–24.
- 11Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715–21.
- 12Jayaram L, Pizzichini MM, Cook RJ et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. [Internet]. Eur Respir J 2006; 27: 483–94.
- 13Chlumsky J, Striz I, Terl M, Vondracek J. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res 2006; 34: 129139.
- 14Licona-Limón P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013; 14: 536–42.
- 15Nath P, Leung SY, Williams AS et al. Complete inhibition of allergic airway inflammation and remodelling in quadruple IL-4/5/9/13−/− mice. Clin Exp Allergy 2007; 37: 1427–35.
- 16Spits H, Artis D, Colonna M et al. Innate lymphoid cells–a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13: 145–9.
- 17Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013; 19: 977–9.
- 18Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006; 354: 2689–95.
- 19Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 1: CD003559.
- 20Hanania NA, Wenzel S, Rosén K et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187: 804–11.
- 21Humbert M, Busse W, Hanania NA et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2014; 2: 525–536.e1.
- 22Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144–8.
- 23Flood-Page P, Swenson C, Faiferman I et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176: 1062–71.
- 24Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167: 199–204.
- 25Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353: 364–9.
- 26Pauwels RA, Löfdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405–11.
- 27Green RH, Brightling CE, Pavord ID, Wardlaw AJ. Management of asthma in adults: current therapy and future directions. Postgrad Med J 2003; 79: 259–67.
- 28Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973–84.
- 29Nair P, Pizzichini MMM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. [Internet]. N Engl J Med 2009; 360: 985–93.
- 30Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. [Internet]. Lancet 2012; 380: 651–9.
- 31Bel E, Wenzel S, Thompson P et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 1189–97.
- 32Ortega H, Liu M, Pavord I et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198–207.
- 33Castro M, Mathur S, Hargreave F et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125–32.
- 34Busse WW, Katial R, Gossage D et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010; 125: 1237–1244.e2.
- 35Laviolette M, Gossage DL, Gauvreau G et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132: 1086–1096.e5.
- 36Castro M, Wenzel SE, Bleecker ER et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2: 879–90.
- 37Brightling CE, Bleecker ER, Panettieri RA et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014; 2: 891–901.
- 38Gauvreau G, Boulet L-P, Cockcroft D et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011; 183: 1007–14.
- 39Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. [Internet]. N Engl J Med 2011; 365: 1088–98.
- 40Piper E, Brightling C, Niven R et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2012; 365: 1088–98.
- 41Boever E, Ashman C, Cahn A et al. Efficacy and safety of an anti–IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol 2014; 133: 989996.e4.
- 42Corren J, Busse W, Meltzer E et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181: 788–96.
- 43Wenzel S, Ford L, Pearlman D et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455–66, DOI: 10.1056/NEJMoa1304048.
- 44Nair P, Gaga M, Zervas E et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012; 42: 1097–103.
- 45Chesné J, Braza F, Mahay G, Brouard S, Aronica M, Magnan A. IL-17 in severe asthma: where do we stand? Am J Respir Crit Care Med 2014; 190: 1094–101.
- 46Busse WW, Holgate S, Kerwin E et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188: 1294–302.
Citing Literature
